From £6.99 per month
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

A Letter to Stuart Ashman about that death spiral he now admits has been a disaster

By Tom Winnifrith, the Sheriff of AIM | Monday 11 March 2024

Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.

At least Stuart Ashman of Skinbiotherapeutics (SBTX) has now admitted that the death spiral taken out with CLG Capital is a very bad financing option as some of us pointed out right from the start, and were told we did not know what we were talking about!. He says that he will not draw down any more on the facility but, after two conversions, there are still £1.47 million of loan notes outstanding.
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.

Subscribe to our newsletter

Daily digest of our latest stories.

Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was



Anpario – a recovery Buy?...

Thursday »


Bearcast issue update: all should be well



Oracle Power: Cynical Foul

Time left: 07:56:01